Evidence map›Paper›PMID 26642200›Full record

ArticlePloS one2015

Identification of New Molecular Entities (NMEs) as Potential Leads against Tuberculosis from Open Source Compound Repository.

Sudha Sravanti Kotapalli, Sri Satya Anila Nallam, Lavanya Nadella, Tanmay Banerjee, Haridas B Rode, Prathama S Mainkar, Ramesh Ummanni

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Sudha Sravanti KotapalliCentre for Chemical Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500 007, India.
Sri Satya Anila NallamCentre for Chemical Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500 007, India.
Lavanya NadellaDivision of Natural Product Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500 007, India.
Tanmay BanerjeeSyngene International Ltd., Biocon park, Bangalore - 560 099, India.
Haridas B RodeDivision of Natural Product Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500 007, India.
Prathama S MainkarDivision of Natural Product Chemistry, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500 007, India.
Ramesh UmmanniCentre for Chemical Biology, CSIR-Indian Institute of Chemical Technology, Hyderabad - 500 007, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to provide a number of diverse and promising early-lead compounds that will feed into the drug discovery pipeline for developing new antitubercular agents. The results from the phenotypic screening of the open-source compound library against Mycobacterium smegmatis and Mycobacterium bovis (BCG) with hit validation against M. tuberculosis (H37Rv) have identified novel potent hit compounds. To determine their druglikeness, a systematic analysis of physicochemical properties of the hit compounds has been performed using cheminformatics tools. The hit molecules were analysed by clustering based on their chemical finger prints and structural similarity determining their chemical diversity. The hit compound library is also filtered for druglikeness based on the physicochemical descriptors following Lipinski filters. The robust filtration of hits followed by secondary screening against BCG, H37Rv and cytotoxicity evaluation has identified 12 compounds with potential against H37Rv (MIC range 0.4 to 12.5 μM). Furthermore in cytotoxicity assays, 12 compounds displayed low cytotoxicity against liver and lung cells providing high therapeutic index > 50. To avoid any variations in activity due to the route of chemical synthesis, the hit compounds were re synthesized independently and confirmed for their potential against H37Rv. Taken together, the hits reported here provides copious potential starting points for generation of new leads eventually adds to drug discovery pipeline against tuberculosis.

Indexed as

Antitubercular AgentsDrug Evaluation, PreclinicalHep G2 CellsHumansMycobacterium bovisMycobacterium smegmatisMycobacterium tuberculosisTuberculosisAntitubercular Agents

Identifiers

PMID26642200
PMCPMC4671662

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.